Introduction
Although contraceptive methods are used to control population growth rates, conventional contraceptions in use today cause various side effects. Therefore, immunocontraception has been developed as a candidate for a safer and reversible approach. One of the immunocontraceptive candidates currently being developed is pellucid zone (ZP), which inhibits the interaction between sperm and ovum. The human ZP-specific glycoprotein molecule consists of ZP1, ZP2, ZP3, and ZP4. Among those components, ZP3 plays an important role as the primary receptor to identify the spermatozoa and stimulate the acrosome reaction [1] [2] [3] .
Follicles are present in various sizes to represent the various folliculogenesis stages. The enlargement of follicle diameter is an important morphological aspect as the follicles enter the growth stage and result in granulosa cell proliferation, an increase in the size of oocytes and the beginning of theca formation. The size of the Objective: To evaluate the effects of pellucid zone 3 monoclonal antibodies against B-cell lymphoma 2 (BCL-2) expression and mice follicle diameter at various time periods. Methods:
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follicle diameter can be used to determine the follicle's viability [4] [5] [6] .
The ZP antibodies are proposed to affect the function of ovarium granulosa cells [7] . Granulosa cells are a location where B cell lymphoma 2 (BCL-2) is expressed, which is very important to maintain the cell's viability [8] . There is an discussed thoroughly issue about the potential of immunocontraception, hence the research on the potential of immunocontraception with glycoprotein ZP and ZP antibodies is still being conducted to assess its effectiveness in preventing fertilization and its impact on ovarian function [3] . 
Materials and methods

The treatment allocation
Prior to the treatment, acclimatization was conducted for 10 d so that the mice could adapt to the new environment. Next, a vaginal swab was performed to determine whether the mice were in the estrous phase.
Mice in estrous were directly treated by intramuscular (im) injection of 50 µL of PBS in control groups (group 1, 2 and 3) and 50 µL Mab bZP3 in the treatment groups (group 4, 5, 6).
Immunohistochemistry and hematoxylin and eosin staining
Mouse ovaries were dissected and histologically prepared for immunohistochemistry and hematoxylin and eosin staining (Figure 1 
Observation of BCL-2 expression
BCL-2 expression in ovaries was analyzed using a light microscope equipped with a digital camera and image processing software.
Data from each sample was observed in five different fields of view (LP) with 400 暳 and 1 000 暳 magnification. BCL-2 expression in pre-antral follicle granulosa cells and antral follicle was evaluated semiquantitatively using the Remmele method.
Data from each sample assessed semi-quantitatively according to the method that has been modified by Novak et al. [18] , where the index scale Remmele (Immuno Reactive Score/IRS) is the multiplication of scores cell percentages immune-reactive to determine the score color intensity on the immuno-reactive cell (Table   1) . Data from each sample is the average value of IRS observed in five different visual fields at 400 暳 and 1 000 暳 magnification. 
The measurement of follicle diameter
Follicles were identified after hematoxylin and eosin staining using a light microscope with 400 暳 magnification equipped with a digital camera and image processing software. The measurements were conducted after the microscope was calibrated to ensure accuracy.
The area of follicles was measured up to the external theca layer using image raster 3 software to determine follicles diameter using following formulae (1) . Therefore, to calculate the area of a circle was used to get the radius (r) of the follicle using following equation
The acquired value of r then entered into the formulae to get the diameter of the follicle, as:
L= Follicle area, r= radius (2) 3. Results
Analysis of BCL-2 expression
There was no significant difference in average BCL-2 expression (P>0.05) in the pre-antral follicle and antral on day 5 of observation between the control and treatment groups ( Table 2 ).
On day 10 of observation, there was no significant difference in average BCL-2 expression in the pre-antral follicles between the control and treatment groups (P>0.05) ( Table 2 ). However, there was a significant difference in average BCL-2 expression in the antral follicle (P<0.05). The results of the LSD test showed that the average BCL-2 expression in the treatment groups was lower than that in the control groups.
In addition, there was no significant difference in average BCL-2 expression in the antral and pre-antral follicles on day 20 observations in each control and treatment group (P>0.05) ( Table 2 ).
The effect of Mab bZP3 induction on follicle diameter
The average pre-antral and antral follicle diameters were compared at various observation time. There was no significant difference in average pre-antral and antral follicle diameter on day 5 observation in the control and treatment groups (P>0.05) ( Table 3 ). There was no significant difference in average pre-antral and antral follicle diameters on day 10 observation between control and treatment groups. On day 20 observation, there was no significant difference in average pre-antral and antral follicle diameters between control and treatment groups (P>0.05) ( Table 3 ).
Discussion
The immunocontraception induction/allotment at various observation time is required to evaluate its effectivity and safety.
The condition for an immunocontraception vaccine is able to provide long-term protection for (6-12) mo. However, the immunocontraception vaccine should not be permanent but should have a specific role during the reproduction process without causing side effects in the reproduction process [1] . In this study, after inducing PBS to the control groups and Mab bZP3 to the treatment group, observations of BCL-2 expression were carried out on day 5, day 10 and day 20 in accordance with the mouse estrous cycle.
To acquire reproduction data, the mice must be operated during the estrous phase [15] . The bZP3 post induction could recognize ZP3 as its antigen [14] .
The rabbit's serum produced anti-bZP3 antibodies as an immune response to rabbit bZP3. The rabbit anti-bZP3 identified ZP protein as conserved in cows and rabbits, and the binding between antibZP3 and rabbit ZP3 was also observed in oocytes in several follicle developmental phases during the formation of the ZP. Therefore, anti-bZP3 is able to recognize ZP3 as its target during the formation of the oocyte ZP, which is the last primary follicle phase. found in the granulosa cell intercellular chamber [7] . The granulosa cells play a major role in reducing the viability of follicles [8] , and BCL-2 molecules (prosurvival) are expressed in these granulosa cells [16] . These BCL-2 molecules are important in binding and neutralizing pro-apoptosis proteins that can induce the apoptosis process in granulosa cells. This is consistent with previous results demonstrating that BCL-2 expression is required to support the viability of granulosa cells [8] . Furthermore, a reduction in BCL-2 expression is associated with an increase in follicle atresia [11] .
However, the decrease in BCL-2 expression can be affected by other factors, such as homeostasis between BCL-2 family members that are anti-apoptotic. In addition, the BCL-2 expression is also closely related to gonadotropin levels, where the increase in gonadotropin will increase BCL-2 expression and decrease BAX expression.
Thus, there are many factors that contribute to BCL-2 expression in granulosa cells, including BAD, BID, and FSH, which were not addressed in this study and are expected to decrease BCL-2 expression.
Follicle diameter can be a sign of follicle viability/survival. Many factors are suspected to influence follicle development that may also affect follicle diameter. The development of ovarian follicles is regulated by different endocrine, paracrine and autocrine signaling mechanisms in their coordination of actions to select the particular follicles for ovulation [8] .
The effects of the induction of Mab bZP3 monoclonal antibodies on follicle diameter at different observation time were analyzed in control mice exposed to PBS and in treatment mice exposed to Mab bZP3. One observation time point was selected because the mice required termination. The results were observed once on day 5 for group 1 and 4, on day 10 for group 2 and 5 and on day 20 for group 3 and 6.
The results of day 5 and day 10 showed higher pre-antral follicle diameters in the treatment groups than those in the control groups.
However, the pre-antral follicle diameters in the treatment groups were lower than those in the control groups by day 20. The antral follicle diameters were lower in the treatment groups than in control groups on observation day 5, in contrast to observation day 10 and day 20 when the antral follicle diameters were higher in the treatment groups than in the control groups. There was no significant difference in average pre-antral and antral follicles diameter on days 5, 10 and 20 observation.
Our results showed variable average follicle diameters between the control and treatment groups. The variation in the diameters may result from indirect effects of Mab bZP3 induction. The addition of IgG molecules to the ZP will change its structure [9] . It is expected that many follicles undergo atresia due to the disruption of granulosa cells and oocyte growth due to alteration in ZP structure after Mab bZP3 induction. The alterations in ZP structure are proposed to occur due to lysis of the ZP resulting from the formation of attack complexes on the ZP. The formation of antigen-antibody complexes will activate complement and induce the formation of attack complexes, which will induce the follicular cell apoptotic mechanism and result in follicle atresia [17] .
Follicle atresia can be associated with the reductions in BCL-2 expression in the treatment group at all observation time points in this study. BCL-2 is an important molecule to inhibit apoptosis and prevent follicle atresia. Thus, the BCL-2 expression is important to support the development of follicles and suppress cell death [11] .
The statistical analysis of our data showed no significant difference in the average diameters of pre-antral and antral follicles at different observation time in each control and treatment group (P>0.05).
Therefore, one Mab bZP3 induction does not cause the decrease in follicle diameter at the different observation time suggesting that the induction of Mab bZP3 does not interfere with folliculogenesis as indicated by follicle size. This is the advantage of Mab bZP3 in specifically targeting ZP3-positive cells [14] , without disrupting the other major ovarian cells such as the granulosa cells and oocytes.
In contrast, rat pre-antral follicles cultured with anti-ZP3 antibodies showed a disruption in the development of follicles and oocytes including reduced follicles diameter size in the treatment groups [10] .
The results of this research indicate that Mab bZP3 is a moderately safe immunocontraception candidate. However, further analysis is required to confirm its effectiveness.
These results suggest that Mab bZP3 has the potential to be developed as the safe available immunocontraception materials.
